K2M Group Holdings Inc (KTWO) Receives Average Rating of “Buy” from Analysts

K2M Group Holdings Inc (NASDAQ:KTWO) has received a consensus rating of “Buy” from the fourteen analysts that are presently covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and ten have issued a buy rating on the company. The average 12 month price objective among brokers that have covered the stock in the last year is $24.44.

A number of analysts recently issued reports on the stock. Zacks Investment Research upgraded shares of K2M Group from a “sell” rating to a “hold” rating in a research note on Thursday, January 25th. BidaskClub raised shares of K2M Group from a “hold” rating to a “buy” rating in a report on Wednesday, January 10th. Barclays reissued a “buy” rating and set a $25.00 price target on shares of K2M Group in a report on Tuesday, January 9th. Needham & Company LLC boosted their price target on shares of K2M Group from $20.00 to $23.00 and gave the company a “buy” rating in a report on Tuesday, January 9th. Finally, Wells Fargo & Co downgraded shares of K2M Group from an “outperform” rating to a “market perform” rating and set a $23.00 price target for the company. in a report on Monday, December 4th.

K2M Group (KTWO) traded down $0.11 on Friday, hitting $20.61. 364,638 shares of the stock were exchanged, compared to its average volume of 290,036. The stock has a market capitalization of $897.77, a price-to-earnings ratio of -21.25 and a beta of 1.47. K2M Group has a 12 month low of $16.44 and a 12 month high of $25.99. The company has a debt-to-equity ratio of 0.29, a current ratio of 3.06 and a quick ratio of 1.67.

K2M Group (NASDAQ:KTWO) last posted its quarterly earnings data on Wednesday, November 1st. The medical device company reported ($0.20) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.01). The firm had revenue of $62.65 million for the quarter, compared to analysts’ expectations of $62.69 million. K2M Group had a negative net margin of 16.22% and a negative return on equity of 16.02%. The company’s revenue for the quarter was up 5.6% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.19) EPS. analysts forecast that K2M Group will post -0.85 earnings per share for the current year.

A number of institutional investors have recently modified their holdings of the business. Cubist Systematic Strategies LLC grew its stake in K2M Group by 7,765.0% during the 3rd quarter. Cubist Systematic Strategies LLC now owns 4,719 shares of the medical device company’s stock valued at $100,000 after acquiring an additional 4,659 shares in the last quarter. Rockefeller Financial Services Inc. bought a new stake in shares of K2M Group in the 3rd quarter valued at approximately $105,000. Legal & General Group Plc grew its stake in shares of K2M Group by 41.4% in the 2nd quarter. Legal & General Group Plc now owns 9,561 shares of the medical device company’s stock valued at $232,000 after buying an additional 2,798 shares in the last quarter. Trexquant Investment LP bought a new stake in shares of K2M Group in the 3rd quarter valued at approximately $223,000. Finally, Quantbot Technologies LP boosted its position in K2M Group by 275.9% during the third quarter. Quantbot Technologies LP now owns 10,593 shares of the medical device company’s stock worth $224,000 after purchasing an additional 7,775 shares during the period. Hedge funds and other institutional investors own 98.86% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This piece of content was published by American Banking News and is the property of of American Banking News. If you are reading this piece of content on another site, it was illegally copied and republished in violation of U.S. & international copyright and trademark laws. The legal version of this piece of content can be accessed at https://www.americanbankingnews.com/2018/02/03/k2m-group-holdings-inc-ktwo-receives-average-rating-of-buy-from-analysts.html.

K2M Group Company Profile

K2M Group Holdings, Inc is a medical device company focused on designing, developing and commercializing spine and minimally invasive technologies and techniques. The Company’s solutions are focused on achieving three-dimensional Total Body Balance. Its spine products are used by spine surgeons to treat spinal pathologies, such as deformity (primarily scoliosis), trauma and tumor.

Analyst Recommendations for K2M Group (NASDAQ:KTWO)

Receive News & Ratings for K2M Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for K2M Group and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply